Company: NIVFW
Filing Date: 2025-04-22
Form Type: 20-F
Source: 0001213900-25-033966
Chunk: 0

Company: NewGenIvf Group Ltd
Filing Date: 2025-04-22
Form: 20-F
Item: Item 3
Chunk 0
---
Item 3. Key Information

  [Reserved]  
 ──────────────

  Capitalization and indebtedness  
 ───────────────────────────────────

Not applicable.

  Reasons for the offer and use of proceeds  
 ─────────────────────────────────────────────

Not applicable.

  Risk Factors  
 ────────────────

Risks Related to NewGenIvf’s Business
and Industry

We may not be able to continue operating
as a going concern.

As of December 31, 2024, the
Company’s cash and cash equivalents stood at approximately US$457,740. While the Company does not have immediate challenges to settle
its obligations when payments become due, the Company can make no assurance that it will have sufficient capital to bridge potential financial
and liquidity shortfalls.

The Company is always closely monitoring the market for opportunities
and has also been carrying out various fundraising projects to improve the Company’s cash flow position. As of this report date,
all promissory notes as of December 31, 2024 have been settled, and convertible bonds comprising the Initial Note, the First Mandatory
Additional Note, and the Second Mandatory Additional Note, have been converted into shares in the Company. A further US$2,000,000 of the
Third Mandatory Additional Note was issued subsequent to the 2024 yearend and remains outstanding. Moreover, the Company has access to
an equity line of credit facility of up to US$100,000,000 from White Lion Capital, of which approximately US$7.1 million has been drawn
and become equity to date. As of this report date, the Company holds $2.48m cash in bank and a cash deposit of $1m with a trading platform
company.

The Company can make no assurance
that required financings will be available for the amounts needed, or on terms commercially acceptable to the Company, if at all. If one
or all of these events does not occur or subsequent capital raises are insufficient to bridge financial and liquidity shortfall, there
would likely be a material adverse effect on the Company and its financial statements.

The consolidated financial
statements do not reflect adjustments that would be necessary if the going concern basis was not appropriate. If the going concern basis
was not appropriate for these consolidated financial statements, then adjustments would be necessary in the carrying value of the assets
and liabilities, the reported revenues and expenses, and the balance sheet classifications used. These adjustments could be material.

The fertility market in which NewGenIvf